Samumed
Biosplice Therapeutics (formerly Samumed) is a clinical-stage biotechnology company developing lorecivivint, an investigational disease-modifying drug candidate for osteoarthritis, using its proprietary alternative splicing technology platform to address over 50 million US patients.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Samumed does
Biosplice Therapeutics, Inc., formerly known as Samumed, is a clinical-stage biotechnology company headquartered in San Diego, California. The company develops therapeutics based on its proprietary alternative splicing technology platform, with its lead investigational drug candidate, lorecivivint, positioned as a potential first-in-class disease-modifying treatment for osteoarthritis. The company cites an addressable patient population of over 50 million US osteoarthritis sufferers who currently lack any approved therapy capable of arresting disease progression, framing lorecivivint's clinical development around a large unmet medical need. The corporate website (biosplice.com) serves as the primary information and communication channel, and includes a Publications page, an Our Programs section (covering both the lead osteoarthritis program and an 'Other Programs' tab), and a Careers page, indicating ongoing pipeline and organizational activity.\n\nThe company's product surface is highly concentrated: lorecivivint is identified as its single core product, and the product_overview characterizes the business as a single-asset pharmaceutical development pipeline. No pricing, distribution, or commercial go-to-market mechanics are disclosed, consistent with the company being pre-commercial. Biosplice is structured as a privately held corporation (Inc. designation) with no parent company, no subsidiaries, and no public ticker. Ownership, investor composition, and capitalization history are not provided in the source material, though the company is clearly independent and operating based on an active website presence and copyright notice.\n\nBiosplice's business model is fundamentally a clinical development model rather than a revenue model. With no approved product, no commercial pricing, and no distribution channels, the company generates no product revenue. Any future commercialization would plausibly follow standard pharmaceutical channels — wholesalers, specialty pharmacies, and healthcare providers — contingent on potential FDA approval of lorecivivint. The company does not currently disclose partnerships, licensing agreements, or royalty arrangements, meaning the path to monetization (self-launch, out-license, or co-promote) is not yet determined by publicly available evidence.
Samumed firmographics
Firmographics- Name
- Samumed
- Legal name
- Biosplice Therapeutics, Inc.
- Website
- https://samumed.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Biosplice Therapeutics (formerly Samumed) is a clinical-stage biotechnology company developing lorecivivint, an investigational disease-modifying drug candidate for osteoarthritis, using its proprietary alternative splicing technology platform to address over 50 million US patients.
- Ownership category
- akta.pro rank
Samumed industry classification
Industry- Product category
- Osteoarthritis therapeutics / clinical-stage biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
- akta.pro secondary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
Keywords
Samumed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Marketing channels1 record
Samumed product offering
Product offeringCore offering
Samumed (now Biosplice Therapeutics, Inc.) is a clinical-stage biotechnology company developing lorecivivint, an investigational drug candidate for the treatment of osteoarthritis. The company leverages an alternative splicing technology platform to create small-molecule therapeutics targeting a disease that affects over 50 million US patients for which no disease-modifying drugs are currently available.
Product overview
Biosplice Therapeutics (formerly Samumed) is a biotechnology company focused on developing a single investigational drug candidate called lorecivivint for the treatment of osteoarthritis. The company operates as a single-product pharmaceutical development pipeline, with lorecivivint as the primary therapeutic candidate targeting a condition affecting over 50 million US patients for which no disease-modifying drugs currently exist.
Differentiator
Problem solved
Functional benefit
Products and services
- Lorecivivint Lorecivivint is an investigational drug candidate being developed by Samumed (now Biosplice Therapeutics, Inc.) for the treatment of osteoarthritis, a degenerative joint disease affecting over 50 million US patients for which no drugs are currently available to arrest disease progression. The investigational candidate leverages alternative splicing technology and targets a significant unmet medical need in osteoarthritis therapeutics.
Companies that use Samumed
Customer profileSegments1 record
Ideal customer profiles1 record
Samumed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Samumed partnerships and signals
Strategic signalScale indicators1 record
Recent moves1 record
Expansion highlights3 records
Samumed competitors and assessment
Company assessmentDirect peers
- Bioventus: Commercial-stage company offering osteoarthritis pain management and joint preservation therapies. Comparable to Biosplice as a focus on OA therapeutics, though Bioventus is more diversified across pain management and orthobiologics.
- Kolon TissueGene: Clinical-stage biotech developing cell and gene therapy for osteoarthritis (Invossa). Directly comparable to Biosplice as a late-stage OA therapeutic developer; both companies have focused single-asset OA programs targeting disease modification.
- Mesoblast: Clinical-stage biotech developing cell therapy candidates (e.g., Rexlemestrocel-L) for osteoarthritis and musculoskeletal indications. Comparable to Biosplice as a late-stage clinical biotech targeting structural disease modification in OA.
- Flexion Therapeutics: Was a clinical-stage and commercial biotech focused exclusively on osteoarthritis therapeutics (e.g., Zilretta). Directly comparable to Biosplice as a single-indication OA-focused biotech, providing a useful template for potential commercial dynamics and acquirer interest in the OA space.
- Anika Therapeutics: Specialty therapeutics company with osteoarthritis products including hyaluronic acid-based intra-articular injections. Comparable to Biosplice as an OA-focused therapeutics company, though Anika has commercialized products while Biosplice is still clinical-stage.
- Paradigm Biopharma: Clinical-stage biotech developing injectable pentosan polysulfate sodium for osteoarthritis. Closely comparable to Biosplice as a small-cap clinical-stage biotech focused on OA with a single late-stage asset.
Broad incumbents
- Pfizer: Global pharmaceutical incumbent with broad osteoarthritis-related portfolio (NSAIDs, pain management, and prior JAK inhibitor efforts). Comparable as a potential strategic acquirer or competitor in the OA therapeutic space.
- Novartis: Global pharmaceutical incumbent with broad musculoskeletal and rheumatology portfolio. Comparable as a large pharmaceutical player with strategic interest in OA and the potential to acquire or partner with clinical-stage assets like lorecivivint.
- Eli Lilly: Major pharmaceutical company with investments in immunology and musculoskeletal diseases. Comparable as a broad incumbent interested in large OA patient populations and potential acquirer of clinical-stage biotech assets.
- Amgen: Major biotechnology company with commercial osteoporosis and inflammation franchises. Comparable as a broad incumbent that could view a late-stage OA asset as a strategic fit for its musculoskeletal portfolio.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Samumed social profiles
Digital presenceSamumed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Samumed leadership team
Management profileNumber of profiles
Samumed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Samumed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Samumed
What does Samumed do?
Samumed (now Biosplice Therapeutics, Inc.) is a clinical-stage biotechnology company developing lorecivivint, an investigational drug candidate for the treatment of osteoarthritis. The company leverages an alternative splicing technology platform to create small-molecule therapeutics targeting a disease that affects over 50 million US patients for which no disease-modifying drugs are currently available.
Is Samumed a public or private company?
Samumed is a private company. It is classified as unknown and is currently operating.
When was Samumed founded?
Samumed was founded in -1. It employs 1 to 10 people.
Who are Samumed's main competitors?
Direct peers on record are Bioventus, Kolon TissueGene, Mesoblast, Flexion Therapeutics, Anika Therapeutics and Paradigm Biopharma. Broad incumbents are Pfizer, Novartis, Eli Lilly and Amgen.
Does Samumed have an API?
No public API is recorded for Samumed.
What industry is Samumed in?
Samumed's product category is Osteoarthritis therapeutics / clinical-stage biopharmaceuticals. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.